PDCD1 and neoplasm: ‘Immunologically hot’ tumours, characterised by a high degree of T‐cell infiltration, present a more favourable environment for immune checkpoint inhibitors (ICIs), such as anti‐PD1 and anti‐CTLA4, alone or combined with other therapies.69